A pioneer work performed in 2014 demonstrated for the first time that aggressive prostate cancers had increased MAO-A expression and that knockdown of MAO-A reduced tumor growth and metastasis in vivo through HIF-1α and epithelial-to-mesenchymal transition blockade [12]. The gene discussed is HIF1A; the disease is neoplasm.